NCT07282548Withdrawn
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called lymphocytes. All participants will receive Tazemetostat as prescribed by their doctor in the routine clinical practice. The study will observe how participants respond to the treatment, how long the response lasts, and monitor safety, side effects and how well participants tolerate the treatment.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 27 Nov 2025
- Start date
- Jun 2026
- Primary completion date
- 30 Jun 2031
- Lead sponsor
- Ipsen
- Diseases
- Follicular lymphoma
- NCT number
- NCT07282548
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of strong/moderate Cytochrome P450 (CYP3A) inhibitors
Other illness
- Other hematologic malignancies
Other
- Grade 3B or transformed follicular lymphoma
- Pregnant or breastfeeding
- Participation in another investigational program
Who the study is looking for
- Adults aged 18 years or older
- Histologically confirmed follicular lymphoma grades 1, 2, or 3A
- At least two prior lines of systemic therapy
- Prescribed tazemetostat according to United States prescribing information (USPI)
- Known or planned EZH2 mutation status
- Signed informed consent
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.